The Optimer delivery vehicle was developed to selectively target cells linked to fibrotic liver disease, as part of a fee-for-service partnership with the pharmaceutical company that began in 2020.

“This type of discovery is the ambition of every physician,” says Gorbach, a longtime professor at Tufts University School of Medicine and the chief scientific officer at Optimer Pharmaceuticals in ...

The Yorl business said it is now signing multiple new contracts with global market-leading pharmaceutical companies ...